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Human innate immunity to non-pathogenic species of African
trypanosomes is providedbyhumanhighdensity lipoprotein (HDL)
particles. Here we show that native humanHDLs containing hapto-
globin-related protein (Hpr), apolipoprotein L-I (apoL-I) and apo-
lipoprotein A-I (apoA-I) are the principle antimicrobial molecules
providing protection from trypanosome infection. Other HDL sub-
classes containing either apoA-I and apoL-I or apoA-I andHpr have
reduced trypanolytic activity, whereas HDL subclasses lacking
apoL-I and Hpr are non-toxic to trypanosomes. Highly purified,
lipid-free Hpr and apoL-I were both toxic to Trypanosoma brucei
brucei but with specific activities at least 500-fold less than those of
native HDLs, suggesting that association of these apolipoproteins
within the HDL particle was necessary for optimal cytotoxicity.
These studies show that HDLs can serve as platforms for the assem-
bly of multiple synergistic proteins and that these assemblies may
play a critical role in the evolution of primate-specific innate immu-
nity to trypanosome infection.
High density lipoprotein (HDL)2 has several well established physio-
logical activities. The best understood of these is the ability of HDL to
protect against atherosclerotic cardiovascular disease by promoting the
efflux of excess cholesterol from peripheral tissues and its subsequent
transport to the liver for excretion. In addition, apolipoproteins and
enzymes carried by HDL have antioxidant activities that inhibit the
oxidative modification of low density lipoprotein (LDL), thereby reduc-
ing the atherogenicity of these lipoproteins. A less well known activity of
HDL is an antimicrobial property that protects some primates from
infection by certain eukaryotic pathogens. In these primate species,
HDL apolipoproteins have been proposed to have novel innate immune
protective functions that provide selective protection against infection.
One such innate immune activity in the serum of humans, apes, and
old world monkeys limits the host range of Trypanosoma brucei brucei
to non-primate mammals (1). This activity fractionates with a minor
subclass of humanHDL termed trypanosome lytic factor 1 (TLF-1) that,
like all HDLs, is composed of apolipoproteins, phospholipids, and neu-
tral lipids (2, 3). Trypanosome killing by these cytotoxic HDLs requires
high affinity binding to receptors on the trypanosome surface, endocy-
tosis, and lysosomal localization (4–8). Following lysosomal acidifica-
tion, destabilization of the lysosome membrane is facilitated by either
free radical-mediated lipid peroxidation or pore formation (9–11). Two
HDL-associated proteins have been implicated in the toxicity of TLF-1,
haptoglobin-related protein (Hpr) and apolipoprotein L-I (apoL-I)
(12, 13).
Haptoglobin-related protein differs by only 27 amino acids from
human haptoglobin, an acute phase serum protein that binds hemoglo-
bin released from red blood cells during trauma or infection and trans-
fers the hemoglobin to liver cells for detoxification (14, 15). However,
Hpr does not bind hemoglobin, and its physiological function is
unknown (9, 16). The role of Hpr in T. b. brucei killing was initially
proposed based on its fractionation with TLF-1 and its presence in
lipid-deficient human serum fractions that also contain trypanosome
killing activity (TLF-2) (12, 17, 18). Additionally, the Hpr gene evolved
during primate evolution and is present in all primate species with
trypanolytic sera. An apparent exception is the chimpanzee, which have
the Hpr gene but lack trypanolytic sera and are susceptible to infection
by T. b. brucei. When chimp sera were tested for the presence of Hpr
none was detectable, indicating that although chimps retain the Hpr
gene they lack Hpr in their serum (19).
Another primate-specific protein, apoL-I, has recently been shown to
possess cytotoxic activity against T. b. brucei. ApoL-I is a member of a
multi-gene family on human chromosome 22 consisting of APOLI-
APOLVI (20–22). TheAPOL-I,APOL-II,APOL-III, andAPOL-IV genes
form a distinct cluster and may be the result of recent tandem gene
duplications. Comparative sequence analysis indicates that the APOL-
V-APOL-VI cluster is distinct and has a different origin (23). Consistent
with this view, theAPOL-I-APOL-IV cluster is only detected in primates
(21–23). ApoL-I was initially isolated from normal human serum as a
full-length 42-kDa protein and a 38-kDa truncation product, both of
which are found associated with large HDL particles (20, 22, 23). Sec-
ondary structure predictions based on cDNA sequences identify four
lipid-binding amphipathic -helices (20). Based on its proposed struc-
ture, apoL-1 has been suggested to function as a catalyst for lipid trans-
fer, although this activity has not been demonstrated (20, 22). ApoL-I is
expressed in a wide range of tissues, and apoL-I mRNA is most abun-
dant in lung, pancreas, liver, placenta, and spleen (22). Studies with
purified apoL-I from human serum and recombinant apoL-I expressed
inmammalian cells have shown that apoL-I kills T. b. brucei (13). A role
for apoL-I inT. b. brucei killing was supported both by the lack of apoL-I
in the serum of chimpanzees, which are susceptible to T. b. brucei, and
its presence in the serum of gorillas, which are resistant to T. b. brucei.
However, other T. b. brucei-resistant primates such as the baboon and
the sootymangabey do not contain apoL-I in their serum, althoughHpr
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is present (19, 24). These inconsistencies have led us to re-investigate
the role of Hpr and apoL-1 in T. b. brucei killing.
In the studies reported here we show that Hpr and apoL-I assemble
into the same native human HDL particle, that purified apoL-I and Hpr
are both T. b. brucei-specific toxins, and that assembly of these proteins
into the sameHDL particle resulted in a synergistic increase in trypano-
lytic activity. Our results suggest that HDL assembly and remodeling
play important roles in the formation of multi-component assemblages
in the circulation that may accentuate innate immune protection
against infectious agents.
MATERIALS ANDMETHODS
Purification ofHumanHDLs andApolipoproteins—HumanHDLswere
purified by differential flotation on sodium bromide gradients as described
previously (3). Briefly, normal human blood was obtained from healthy
fasted donors, and serum was immediately separated from blood cells by
centrifugation at 4 °C for 10min at 9,500 rpm in a Sorvall SS-34 rotor. The
serum was adjusted to 0.5 mM EDTA, and density was adjusted to 1.063
g/ml by the addition of sodium bromide. Very low density lipoprotein
(VLDL)andLDLwere removedbycentrifugationat 18 °C for23hat50,000
rpm in a Beckman Ti70 rotor. HDL was sequentially isolated by adjusting
theLDL-deficient serumto1.26g/ml followedbycentrifugationat18 °C for
42h at 50,000 rpm in aBeckmanTi70 rotor.TheHDL-containing floatwas
dilutedwithphosphate-buffered saline containing 3mMEDTA(PBSE) and
dialyzed against PBSE to remove the sodium bromide. These total human
HDLswere then fractionated by immunoaffinity absorptionwith anti-Hpr
or anti-apoL-I. BoundHDL fractionswerewashedwith PBSE, eluted using
100 mM glycine at pH 2.0, and immediately neutralized by the addition of
100mMTris (pH7.5).A fractionofHDLwas identified thatwasdeficient in
both apoL-I and Hpr after sequential immunoaffinity selection with anti-
Hpr and anti-apoL-I columns. This unbound fraction of HDL represented
99% of the starting HDL and lacked trypanolytic activity. All HDL frac-
tions were characterized by in vitro T. b. brucei lysis assays and Western
blots. For purification of apolipoproteins, total humanHDLswere first sol-
ubilized in PBSEby the addition of either deoxycholate orCHAPS to a final
concentration of 10mM. Individual apolipoproteins were immunoaffinity-
purifiedbyanti-Hproranti-apoL-I columnchromatography.Purityof apo-
lipoprotein fractions was determined by SDS-PAGE andWestern blotting
as described (3).
Antibodies and Affinity Columns—Antibodies used in these stud-
ies were either purchased commercially (anti-apo-B, anti-apoA-I,
and anti-haptoglobin from Sigma; anti-apoL-I (anti-apoL-I (1) in
Fig. 1B) from Santa Cruz Biotechnology, Inc.) or were prepared by
FIGURE 1. Lysis of T. b. brucei by human HDLs is inhibited by anti-apolipoprotein
antibodies. A, apolipoprotein L-I and Hpr fractionate with human HDL particles. Unla-
beled lane, Coomassie-stained sample. Labeled lanes, Western blots probed with mono-
clonal antibodies to apo-AI (ApoAI), apoL-I (ApoLI), andHpr. B, antibody inhibition of lysis
of T. b. brucei by human HDL. The addition of monoclonal antibodies against apoA-I,
apoL-I (anti-apoL-I (2)), Hpr, or polyclonal sera against haptoglobin or apoL-I (anti-apoL-I
(1)) inhibited HDL lysis of T. b. brucei, whereas the addition of antibodies against the LDL
apolipoprotein B had no effect on lysis.
FIGURE 2. Lytic activity of purified and reconsti-
tuted Hpr and apoL-I. A, purified Hpr was ana-
lyzed by SDS-PAGE, Coomassie staining (far left
lane), andWestern blot. B, purified apoL-I was ana-
lyzed by SDS-PAGE, Coomassie staining (far left
lane), and Western blot. C, unbound apolipopro-
teins analyzed by SDS-PAGE, Coomassie staining
(far left lane), and Western blot were found to be
efficiently depleted of Hpr and apoL-I. D, the
trypanosome lytic activity of purified apoL-I (●)
was 0.14 units/g and the lytic activity of Hpr (E)
was 0.10 units/g, whereas HDL apolipoproteins
depleted of apoL-1 and Hpr were not lytic to T. b.
brucei (f). E, specific activities of purified Hpr and
apoL-I and mixtures of the purified apolipopro-
teins (gray bars). Specific activities of reconstituted
Hpr, apoL-I, and both proteins into HDL particles
(black bars). Reconstituted HDL subclasses all con-
tained 10 g of nonlytic human HDL and the fol-
lowing amounts of purified apolipoproteins: 12.5
gofpurifiedHpr and2.5gofpurifiedapoL-I (5:1
ratio) for apoA-I/Hpr/apoL-I; 12.5 g of Hpr for
apoA-I/Hpr; and2.5gof apoL-I for apoA-I/ApoL-I.
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hyperimmunization of mice with purified human TLF and the pro-
duction of hybridoma cell lines expressing monoclonal antibodies
against apoL-I (anti-apoL-I (2) in Fig. 1B) and Hpr (3). Affi-gel 10
(Bio-Rad) was used as described by the manufacturer to couple puri-
fied fractions of monoclonal anti-apoL-I and anti-Hpr to make affin-
ity chromatography columns.
Trypanosome Lysis Assays—Trypanosome lysis was evaluated by
phase-contrast microscopy following the incubation of T. b. brucei
clonal cell line IlTat 1.3 for 2 h at 37 °C in the presence of either purified
HDLs or individual apolipoproteins. For antibody inhibition studies, 15
g of the indicated antibody or sera was included. For assays with indi-
vidual apolipoproteins, 15 g of anti-apoL-I was added to Hpr assays,
and 15 g of anti-Hpr was added to apoL-I assays. Each lysis assay
contained 3 106 trypanosomes in 300 l of assay buffer. Results pre-
sented in this paper were from samples assayed in triplicate, and S.E. is
indicated. Methods for the purification of trypanosomes, standard lysis
assay conditions, and the specificity of this assay for T. b. brucei have
been described previously (3).
Mixing and Reconstitution Experiments—For the mixing of Hpr and
apoL-I without reconstitution, 2.5 g of purified Hpr and 0.75 g of
purified apoL-I were incubated together in the presence of 5 g/ml
inactive human HDLs for 3 min on ice prior to the addition of trypano-
somes and incubation at 37 °C for 2.5 h. For reconstitution, inactive
human HDLs at 10 g/ml were incubated with 12.5 g of purified Hpr,
2.5g of purified apoL-I or 12.5g ofHpr plus 2.5g apoL-I (5:1) in the
presence of 10 mM sodium deoxycholate. Detergent concentration was
reduced to 0.08 pM by dialysis to allow particles to re-form (25, 26).
Reconstituted HDL samples (1 g) were tested in standard lysis assays
as described. Reconstituted particles were characterized by affinity
chromatography using anti-Hpr and anti-apoL-I, and the efficiency of
apoL-I and Hpr reconstitution into an HDL particle was evaluated by
SDS-PAGE and Western blot.
Radioiodination and Binding of HDL Subclasses—The different HDL
subclasses were purified as described above. Each subclass was radiola-
beled with 1 mCi of 125I using 1,3,4,6-tetrachloro-3,6-diphenlylgly-
couril (Iodogen) as the catalyst (Sigma). Labeled HDLs were separated
from unincorporated 125I by filtration on PD-10 columns (Amersham
Biosciences). SDS-PAGE gels and autoradiography confirmed incorpo-
ration of the label with the apolipoproteins. Labeled HDL was added at
the indicated concentrations to T. b. brucei, 3  107/ml, in F12 media
containing 5% fetal bovine serum and incubated at 4 °C for 16 h (6).
Incubations included a 100-fold excess of unlabeled, nonlytic human
HDLs (Hpr- and apoL-I-deficient fraction of the total HDL) to compete
for general HDL binding. Cells were washed three times with PBSE, and
the amount of bound HDL was measured by scintillation counting.
MALDI-TOF Mass Spectrometry and Sample Preparation—Highly
purified TLF was prepared by sequential flotation on sodium bromide
gradients followed by immunoaffinity purification with anti-Hpr. Sam-
ples were separated under non-reducing conditions on 12% SDS-poly-
acrylamide gels. Gels were stained with Coomassie Blue and destained
with 20% isopropanol and 5% methanol, and protein bands were man-
ually excised for MALDI-TOF analysis. Gel pieces were macerated and
washed with 50% aqueous acetonitrile to remove SDS, salts, and stain,
dried to remove solvent, rehydrated in a solution containing trypsin (12
ng/l; Roche Applied Science), and incubated overnight at 37 °C. Tryp-
tic peptides were recovered, concentratedwith a Centricon device (Mil-
lipore), and desalted using a Zip-Tip (Millipore), and peptides were
eluted with acetonitrile. Samples were spotted onto a gold target plate
for MALDI-TOF analysis using a PE-Biosystems Voyager Elite instru-
ment (Framingham, MA). Peptide peaks were submitted for analysis
with publicly available “Mascot” software (www.matrixscience.com).
RESULTS
Previous studies have shown that themajority of trypanosome killing
activity in human serum fractionates with HDLs (2, 3). We have pre-
sented evidence that a minor subclass of HDL containing Hpr was
trypanolytic, whereas others have shown that apoL-I is toxic to T. b.
brucei (12, 13). These apparently disparate findings were initially inves-
tigated by testing the ability of antibodies raised against apoA-I, Hpr,
and apoL-I to neutralize trypanosome killing. Antibodies against these
apolipoproteins were incubated with total human HDL, and the speci-
ficity of each antibody was shown byWestern blotting (Fig. 1A). Each of
the antibodies showed a characteristic inhibition of trypanosome lysis
by human HDLs (Fig. 1B). Even at high antibody concentrations (data
not shown) we failed to observe complete inhibition of trypanosome
lytic activity using only a single antibody against Hpr or apoL-I. This
suggested that multiple toxins might be present in the human HDL
preparation. Inhibition of lysis by anti-apoA-I was expected, because
TABLE ONE
Trypanolytic activity of purified Hpr and apoL-I, reconstituted HDL subclasses, and native HDL subclasses
Protein Specific activity Recovered activity Recovered activity
g units/g units %
Purified apolipoproteina
Hpr 562 0.10 56 75.7
ApoL-I 130 0.14 18 24.3
Reconstituted HDL subclassb
ApoA-I/Hpr/ApoL-I 1.10
ApoA-I/Hpr 0.24
ApoA-I/ApoL-I 0.28
Native HDL subclassc
ApoA-I/Hpr/ApoL-I 330 83.3d 27,498 99.3e
ApoA-I/Hpr 240 0.5d 115 0.4e
ApoA-I/ApoL-I 116 0.8d 89 0.3e
ApoA-I 2.51e5 0.0d 0 0.0e
a Apolipoproteins purified from HDLs as described in the Fig. 2 legend.
b ReconstitutedHDL subclasses all contained 10g of non-lytic humanHDLand the following amounts of purified apolipoproteins: 12.5g of purifiedHpr and 2.5g of purified
apoL-I (5:1 ratio) for apoA-I/Hpr/apoL-I; 12.5 g of Hpr for apoA-I/Hpr; and 2.5 g of apoL-I for apoA-I/ApoL-I.
c Apolipoproteins as described in the Fig. 5 legend.
d A lytic unit is defined as the amount of protein needed to lyse 50% of the trypanosomes in a standard lysis assay following a 2-h incubation at 37 °C (3).
e Recovered activity was calculated from total activity purified from a unit of blood.
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apoA-I is a ubiquitous component of all HDL particles. However, it is
unlikely that apo A-I is the active toxin for trypanosomes in HDLs
because previous studies using both purified human apoA-I and recom-
binant apoA-I have shown that alone it lacks the ability to lyse trypano-
somes (26, 27). In addition, 99% of the total human serum apoA-I is
associated with HDLs that lack trypanolytic activity (28). Antibodies to
proteins absent from lytic HDLs, such as apolipoprotein B, the major
protein component of LDL particles, did not inhibit trypanosome lysis
(Fig. 1B). Based on these results we focused on the potential role of both
Hpr and apoL-I as active toxins to T. b. brucei.
Because both Hpr and apoL-I have been implicated as toxins to T. b.
brucei, the relative killing activity of these apolipoproteins was evalu-
ated. We immunoaffinity purified Hpr and apoL-I from detergent-sol-
ubilized human HDLs and tested their activity in trypanosome lysis
assays (Fig. 2). The purity of the fractions was determined by Coomassie
staining andWestern blotting (Fig. 2,A–C). TheHpr fraction contained
no detectable apoL-I, whereas the apoL-I fraction contained a trace
amount of Hpr (Fig. 2,A and B). The apoL-I- andHpr-depleted fraction
contained predominantly apoA-I, apolipoprotein A-II, and albumin by
Coomassie and Western blotting (Fig. 2C). Purified Hpr and apoL-I
were tested for trypanosome lytic activity (Fig. 2D). Trypanosomes
incubated with increasing concentrations of purified Hpr or apoL-I
were killed in a dose-dependent manner with specific activities of 0.10
units/g and 0.14 units/g, respectively (TABLE ONE). The apoL-I-
and Hpr-depleted fraction, containing all other proteins present in
human HDLs, had no lytic activity. These results demonstrate, for the
first time, that Hpr and apoL-I are both toxic toT. b. brucei and account
for all lytic activity observed in human serum HDLs.
Although our analysis of purified Hpr and apoL-I indicated that both
are toxins, we observed a significant reduction in lytic activity as com-
pared with native HDL particles. The purified proteins have specific
activities 600–800-fold less than those of native HDLs, indicating
that maximal activity may require assembly into an HDL particle or a
possible synergistic interaction between the two proteins. We first
assayed mixtures of purified Hpr and apoL-I (3:1 molar ratio) in
trypanosome lysis assays and found only an additive increase in
trypanosome killing (Fig. 2E and TABLEONE). These results suggested
that assembly of Hpr and apoL-I into an HDL particle may be required
for maximal trypanolytic activity. To test this possibility we used con-
ditions established previously for the reconstitution of HDLs (25, 26).
FIGURE 3.MALDI-TOF analysis of apolipoproteins fromHpr-containing humanHDL.A,Coomassie-stained SDS-polyacrylamide gel of apolipoproteins fractionated fromhuman
HDL and purified by immunoaffinity chromatographywith anti-Hpr. B,MALDI-TOF spectra of apoA-I, Hpr dimer, and apoL-I full-length bands. The tryptic peptides identified for each
of these proteins is shown in TABLE TWO.
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Hpr and apoL-I were reconstituted with nonlytic human HDL at a
molar ratio of 5:1, mimicking the ratio of Hpr to apoL-I seen in HDL.
Reconstituted particles containing only Hpr or apoL-I had specific
activities of 0.24 units/g or 0.28 units/g, respectively, whereas parti-
cles containing both Hpr and apoL-I showed an 5-fold increase in
specific trypanosome killing activity to 1.10 units/g (Fig. 2E and
TABLE ONE). These findings demonstrate that the assembly of Hpr
and apoL-I into the same HDL particle results in enhanced killing of
T. b. brucei. This observation suggested that native HDL subclasses
containing bothHpr and apoL-I likely have a high specific activity forT.
b. brucei killing and play a major role in human innate protection from
trypanosome infection. We therefore decided to fractionate native
HDLs into subclasses containing either Hpr or apoL-I or both proteins
and to examine the lytic activity of these native HDL particles.
HumanHDLwas initially fractionated into Hpr-containing andHpr-
depleted particles by immunoabsorption with anti-Hpr. Analysis of the
Hpr-containing HDLs by MALDI-TOF mass spectrometry and West-
ern blot identified apoA-I, apoA-II, apoL-I, and Hpr as components of
this subfraction of human HDL (Fig. 3, A and B, TABLE TWO, and Fig.
4A). The unambiguous identification of Hpr and apoL-I was compli-
cated, because both proteins are encoded by multi-gene families in
humans. Hpr was distinguished from human haptoglobin based on
detection of three tryptic fragments unique to Hpr (amino acids 2–15,
34–50, and 220–233). Similarly, apoL-I was distinguished from other
apoL family members (II–VI) based on six tryptic fragments unique to
apoL-I (amino acids 64–90, 134–141, 219–231, 276–290, 291–305,
and 306–316) (TABLE TWO). Hpr was present both as a heterodimer
(/) (45 kDa) and heterotetramer ((/)2) (92 kDa), and both the full-
length apoL-I (42 kDa) and a previously described N-terminal trunca-
tion (39 kDa) were detected (20). Based on Coomassie staining, this
subclass of human HDL contains roughly stoichiometric amounts of
apoA-I andHpr and sub-stoichiometric amounts of apoA-II and apoL-I
(Fig. 4A). Hpr-containing HDLs account for nearly 98% of the recover-
able lytic activity present in human HDLs with an estimated specific
activity of 20 units/g (Fig. 4C). The major apolipoproteins in the Hpr-
depleted HDLs were apoA-I and apoA-II; a small amount of apoL-I was
also detected by Western blot (Fig. 4B). The Hpr-depleted HDLs con-
tained2% of the recovered T. b. brucei lytic activity with an estimated
specific activity of 0.04 units/g (Fig. 4D).
Two critical conclusions can be made based on these studies. First, a
significant fraction of apoL-I is associated with Hpr-containing HDL.
Second, most of the trypanocidal activity of human HDL is associated
withHpr-containing subclasses. However, these experiments also dem-
onstrated that a small but reproducible portion of the trypanosome lytic
TABLE TWO
Peptide fragments identified byMALDI-TOFmass spectrometry of trypsin-digested apolipoproteins present in Hpr-containing human HDL
Predicted
mass
Observed
Mass Amino acid sequence
a Amino acid
numbers
Da Da
Hpr 2014.314 2013.04 FPKPPEIANGYVEHLFR 34–50
1845.175 1844.04 VVLHPNYHQVDIGLIK 178–193
1630.966 1499.88 SDLGAVISLLLWGR 2–15
1543.656 1542.75 VGYVSGWGQSDNFK 220–233
920.035 920.51 GSFPWQAK 113–120
ApoL-I 2956.348 2955.42 VSTQNLLLLLTDNEAWNGFVAAAELPR 64–90
2773.051 2487.18 EFLGENISNFLSLAGNTYQLTR 241–262
1630.729 1630.94 VTEPISAESGEQVER 291–305
1595.821 1595.93 WWTQAQAHDLVIK 219–231
1590.762 1590.97 ANLQSVPHASASRPR 276–290
1349.428 1331.74 NWHDKGQQYR 113–122
1274.455 1274.75 VNEPSILEMSR 306–316
1254.454 1236.75 NWFLKEFPR 123–131
1105.259 1105.68 LNILNNNYK 367–375
975.023 974.60 SKLEDNIR 134–141
918.061 900.61 KALDNLAR 98–105
ApoA-I 2636.855 2618.28 EQLGPVTQEFWDNLEKETEGLR 86–107
1833.929 1815.86 DSGRDYVSQFEGSALGK 48–64
1668.864 1650.89 DLATVYVDVLKDSGR 37–51
1612.756 1612.80 LLDNWDSVTSTFSK 70–83
1532.754 1514.81 VSFLSALEEYTKK 251–263
1485.66 1453.72 VDPLRAELQEGAR 143–155
1429.61 1411.70 KWQEEMELYR 131–140
1386.565 1386.71 VSFLSALEEYTK 251–262
1252.389 1380.72 VQPYLDDFQKK 121–131
1301.422 1301.66 THLAPYSDELR 185–195
1283.421 1283.59 WQEEMELYR 132–140
1252.389 1252.67 VQPYLDDFQK 121–130
1230.470 1230.71 QGLLPVLESFK 240–250
1175.307 1157.63 LEALKENGGAR 202–212
1031.192 1031.53 LSPLGEEMR 165–173
1012.174 1012.58 AKPALEDLR 231–239
a Unique Hpr peptides as compared to haptoglobin and unique apoL-I peptides as compared to apoL-II through apoL-VI are underlined.
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activity was associated with apoL-I-containing HDLs that are deficient
in Hpr (Fig. 4D). Additionally, the stoichiometry of the apolipoproteins
in the Hpr-containing subclass suggested that it contained a mixture of
particles containing apoA-I, apoL-I, and Hpr as well as particles con-
taining apoA-I and Hpr but lacking apoL-I (Fig. 4A).
Based on these initial fractionation studies, wewanted to better estab-
lish the distribution of Hpr and apoL-I in HDL subclasses as well as the
relative distribution of trypanosome lytic activity in these subclasses.
HDL was purified by sequential immunoabsorption first with anti-Hpr
immediately followed by anti-apoL-I separation (Fig. 5A). Four distinct
classes of HDLwere fractionated based on apolipoprotein composition,
namely HDLs containing the following: 1) apoA-I, Hpr and apoL-I; 2)
apoA-I and Hpr; 3) apoA-I and apoL-I; and 4) apoA-I but not Hpr or
apoL-I. The composition of each of these HDL subclasses was deter-
mined by SDS-PAGE andWestern blot analysis with anti-apoA-I, anti-
Hpr, or anti-apoL-I (Fig. 5, B–E). Because apoA-I is a ubiquitous com-
ponent of HDL subclasses we anticipated that all subclasses would
contain apoA-I. Based on the recovery of protein in the different sub-
classes, it appeared that most of the HDL-associated Hpr and apoL-I
co-purified as a complex (TABLE ONE). In vitro lysis assays indicated
that this HDL subclass contained 99% of the recovered trypanosome
lytic activity and had a specific lytic activity of 83.3 units per g of
protein (Fig. 5F and TABLE ONE). The HDL subclasses containing
either apoA-I and Hpr or apoA-I and apoL-I also had lytic activity but
contributed only 0.4% and 0.3% of the recovered lytic activity, respec-
tively, and the specific activity of both the apoA-I and Hpr and the
apoA-I and ApoL1 subclasses was reduced 100-fold to 0.5 and 0.8
units/g, respectively (Fig. 5G and TABLEONE). HDLs not containing
either Hpr or apoL-I but containing apoA-I were inactive, confirming
that apoA-I itself is not trypanolytic (Fig. 5G and TABLE ONE).
Together, these studies indicate that themajority of trypanolytic activity
of human HDLs is associated with particles containing both Hpr and
apoL-I and that the specific activity of this HDL subclass is higher than
that of HDLs containing either Hpr or apoL-I alone.
Studies were initiated to investigate the mechanism of synergy
between Hpr and apoL-I. The cellular pathways for Hpr and apoL-I
killing of T. b. brucei may share common characteristics, because both
require cell surface receptors and intracellular trafficking to the lyso-
some (6, 13). To determine whether the enhanced killing activity by
HDLs containing both Hpr and apoL-I was a consequence of preferen-
tial recognition by trypanosome receptors, the binding of HDLs con-
taining either apoL-I alone, Hpr alone, or both apolipoproteins was
compared.WhenT. b. bruceiwas incubated with the three subclasses of
HDL, no significant differences in binding were observed after 3 and
16 h at 1 and 5 g/ml (Fig. 6; data not shown for the 3-h time point).
These results indicate that the increased lytic activity ofHDL containing
both Hpr and apoL-I is a consequence of intracellular events following
cell surface binding.
DISCUSSION
Innate immunity confers first-line host defense against microbial
pathogens and generally operates in conjunction with adaptive immu-
nity to combat infection (29). African trypanosomes pose a unique chal-
lenge to the mammalian host because a single parasite can establish
infection, and the adaptive immune response is largely ineffective
because of antigenic variation (30). Therefore, human resistance toT. b.
brucei infection is entirely dependent on innate immunity and must
provide sterile protection against challenging parasites. We show that
the human serum HDL apolipoproteins apoL-I and Hpr are both toxic
to trypanosomes and that assembly of these proteins into the sameHDL
particle is necessary for maximal protection against infection by T. b.
brucei. Therefore, the results presented here establish a new paradigm
for our understanding of the role of HDL as antimicrobial complexes.
Haptoglobin-related protein and apoL-I have both been previously
proposed as the human serum proteins responsible for T. b. brucei kill-
ing (12, 13). Although the role of apoL-I was directly evaluated with
recombinant and native affinity-purified protein, the potential toxicity
of Hpr was based largely on inference (13, 19). When Hpr and apoL-I
were purified from total human serum HDL preparations by immuno-
affinity chromatography, we were able to confirm that both were toxic
to T. b. brucei and that the specific activities of the two proteins were
comparable (Fig. 2). However, the specific activity of the individual puri-
FIGURE 4. The trypanosome lytic activity frac-
tionates with Hpr-containing HDLs. Total
human HDLs were separated by immunoaffinity
absorption with anti-Hpr. A, Hpr-containing HDLs
were analyzed by SDS-PAGE, Coomassie staining
(far left lane), and Western blot with anti-apoA-I,
anti-apoL-I, and anti-Hpr. B, Hpr-depleted HDLs
were separated by SDS-PAGE, stained with Coo-
massie (far left lane), and probedwithmonoclonal
antibodies to apoA-I, apoL-I, and Hpr. C, Hpr-con-
taining HDLs were assayed for concentration-de-
pendent killing of T. b. brucei. The specific activity
of the Hpr-containing HDLs was estimated to be
20 units/g Hpr-containing HDL. D, Hpr-depleted
HDLs were assayed for concentration-dependent
killingofT. b. brucei.Thespecific activityof theHpr-
depleted HDLs was estimated to be 0.04 units/g
Hpr-depleted HDL.
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fied apolipoproteins was low relative to that of native HDLs containing
Hpr and apoL-I (Fig. 2 and TABLEONE), suggesting that assembly into
HDL particles may enhance trypanolytic activity. We found that recon-
stitution of each protein individually into an apoA-I-containing HDL
had little effect on specific activity but that assembly of both apoL-I and
Hpr into an apoA-I-containing HDL increased the specific activity for
T. b. brucei killing by5-fold (Fig. 2 and TABLE ONE). These findings
led us to examine native HDL subclasses to determine whether a natu-
rally occurring HDL subclass existed that contained both apoL-I and
Hpr (Fig. 4). Using monoclonal antibodies specific for Hpr and apoL-I,
we were able to physically fractionate four subclasses of human HDLs.
Subclasses of HDL containing either Hpr or apoL-I alone were trypano-
lytic but had low specific activities (0.5 and 0.8 units/g) andwere low in
abundance (0.1% and 0.05% of the total HDL, respectively). An HDL
subclass containing bothHpr and apoL-I, though also low in abundance
(0.13% of the total HDL), had enhanced lytic activity (83.3 units/g).
This subclass of HDL containing apoA-I, Hpr, and apoL-I accounts for
99% of the total recovered trypanosome lytic activity in human HDL.
Previous studies have shown that the killing of T. b. brucei by human
HDLs requires high affinity binding to receptors at the trypanosome cell
surface, endocytosis, lysosomal localization, and acidification (4–7, 16).
The in vitro reconstitution studies and the purification of native HDL
subclasses reported in this paper show that assembly of Hpr and apoL-I
into the sameHDLhas a synergistic effect on trypanosome lytic activity.
The increased lytic activity of HDL particles containing both Hpr and
apoL-I could be due to a number of cellular ormolecular properties.We
have tested the possibility that this HDL subclass binds more efficiently
to trypanosome cell surface receptors then HDLs containing only Hpr
FIGURE 5. Distribution of lytic activity in human
HDL subclasses. A, schematic illustrating the sequen-
tialchromatographicpurificationoftheHDLsubclasses
from total human HDLs. Bound (B) and unbound (U)
fractions are indicated.B,Westernblot ofHDL subclass
containing apoA-I (Apo AI), apoL-I (Apo LI), and Hpr. C,
Western blot of HDL subclass containing apoA-I and
Hpr.D,WesternblotofHDLsubclasscontainingapoA-I
andapoL-I. E,WesternblotofHDL subclassdeficient in
bothHprandapoL-IbutcontainingapoA-I.Lysisassays
were performed as described. F, lytic activity of HDLs
containing apoA-I, apoL-I, and Hpr was 83.3 lytic
units/g (●).G, lytic activity ofHDLs containingapoA-I
andHprwas 0.5 lytic units/g (E), and the lytic activity
of HDLs containing apoA-I and apoL-I was 0.8 lytic
units/g (●). HDLs lacking both Hpr and apoL-I were
completelydeficient in lytic activity (f).
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or apoL-I (Fig. 6). Because there is no difference in the relative binding of
the HDL subclasses, it is likely that increased killing activity is a conse-
quence of activities subsequent to recognition on the trypanosome cell
surface. One possible explanation for the enhanced lytic activity of the
Hpr- and apoL-I-containing HDLs is the stability of these particles in
the trypanosome lysosome. When T. b. brucei was incubated with an
HDL subclass containing both Hpr and apoL-I, the HDL rapidly accu-
mulated in the lysosome but remained largely undegraded (7). Thus,
assembly of Hpr and apoL-I may contribute to resistance to lysosomal
proteases. Alternatively, the increased lytic activity of the HDL particles
containing both Hpr and apoL-I could result from stimulation of the
lytic activities of the individual proteins. Conflicting results on the
mechanism of HDL killing of trypanosomes suggest that there might be
multiple mechanisms involved (9, 10). We have previously proposed
that cytotoxic human HDL kills T. b. brucei by an iron-dependent, lipid
peroxidationmechanism that leads to lysosomalmembrane breakdown
(9). It has also been proposed that HDL killing may be mediated by an
iron-independent killing that involves lysosomal membrane pore for-
mation, and recent studies have shown that recombinant apoL-I is able
to form anionic pores (10, 31). The results presented here clearly dem-
onstrate that Hpr and apoL-I can act independently to kill T. b. bruceii,
and it is interesting to speculate that these proteins may act by different
mechanisms. How these activities might act synergistically is com-
pletely unknown.
The genes for both Hpr and apoL-I are absent in non-primate mam-
mals and evolved during primate evolution through a series of gene
duplication and recombination events (14, 22, 23). Hpr is present in the
serum of all primates that are resistant to T. b. brucei infection (19).
ApoL-I has been reported to be present in the serum of humans and
gorillas but is not present in sera from the baboon or the sooty manga-
bey, both of which have trypanolytic activity (24). Recent results from
studies on chimpanzee sera are consistent with a role for Hpr and
apoL-I in trypanosome killing (19, 24). Chimpanzees contain both the
Hpr gene and the apoL-I gene, but, based onWestern blot results, do not
express either protein, and their serum is not lytic to T. b. brucei. The
lack of expression of both lytic genes is surprising, and the evolutionary
events leading to this loss of expression have not been examined.
Our findings raise the important question of why two serum proteins
have evolved as toxins for African trypanosomes. The evolution of the
haptoglobin and apoL gene families during primate evolution bears
some superficial similarities, suggesting common selective pressures.
We favor a pathway of independent evolution of these proteins in
response to different selective pressures. Although the notion that both
Hpr and apoL-I may have evolved as antimicrobial molecules is appeal-
ing, the conservation of their genes and expression in all humans argues
against African trypanosomes being themajor selective agent. Although
the selective pressures leading to the evolution of these proteins are not
known, the results presented here demonstrate that enhanced innate
host defense is mediated by the assembly of multiple defense molecules
onto a serum HDL platform.
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FIGURE 6. Binding of human HDL subclasses to T. b. brucei. Human HDL subclasses
were radioiodinated and incubated with live T. b. brucei in the presence of a 100-fold
excess of unlabelednonlytic humanHDL at 4 °C for 16 h. Following incubation, unbound
HDLwas removed bywashingwith PBSE, and bound HDLwasmeasured by scintillation
counting. The amount of bound HDL per 3  106 trypanosomes was determined at a
concentration of 1 and 5 g/ml for each HDL subclass. HDL subclasses containing Hpr
and apoL-I (black bars), Hpr (white bars), and apoL-I (gray bars) are shown.
HDLs Are Platforms for Multiple Synergistic Protein Assembly
SEPTEMBER 23, 2005•VOLUME 280•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 32585
 at M
arine Biological Laboratory on April 21, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
